<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01653067</url>
  </required_header>
  <id_info>
    <org_study_id>STORM-2011</org_study_id>
    <secondary_id>2011-001491-20</secondary_id>
    <nct_id>NCT01653067</nct_id>
  </id_info>
  <brief_title>STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma</brief_title>
  <acronym>STORM</acronym>
  <official_title>A Phase II Trial to Evaluate the Safety, Feasibility and Efficacy of a Salvage Therapy Consisting of Temsirolimus Added to the Standard Therapy R-DHAP for the Treatment of Patients With Relapsed or Refractory DLBCL - the STORM Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mathias Witzens-Harig</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johannes Gutenberg University Mainz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Ulm</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Erlangen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Freiburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The STORM-trial consists of two parts. In the part I (dose escalation of Temsirolimus) the
      primary objective is to establish a maximum tolerated dose of Temsirolimus in combination
      with Rituximab and DHAP. Secondary objective is to prove ability to mobilize stem cells in
      patients scheduled to high dose therapy.

      In the part II (full target dose) the primary objective is to evaluate the ORR in patients
      with relapsed diffuse large B cell lymphoma (DLBCL). The secondary objective is to evaluate
      progression free survival (PFS), overall survival (OS) and Toxicity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open label, single arm, phase II study. There will be no placebo usage
      within this trial. In the part I, dose escalation part, of this trial 6 patients will be
      included in each dose level. There will be 4 cohorts, administering up to a maximum of 4
      cycles 25 mg, 50 mg, 75mg or 100mg Temsirolimus in combination with Rituximab and DHAP.

      Treatment regimen part I:

      Part I - Cohort A, B, C, D, X Temsirolimus 25 (A), 50 (B), 75 (C),100 (D) or 15 (X) mg, Day
      1, 8, Rituximab (375 mg/m² day 2) Dexamethasone 40mg day 3-6 Cisplatine 100 mg/m² day 3
      Cytarabine 2x2 g/m² day 4

      ...repeat day 22, up to a maximum of 4 cycles In part I, after inclusion of 6 patients, each
      patient has to receive at least 1 complete cycle w/o dose limiting toxicity until the
      enrollment into the next cohort can be initiated.

      In the part II of the trial 40 patients will be included to receive the full target dose,
      established within the part I of the study.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety, Tolerability and Efficacy of a combination therapy of Temsirolimus added to the standard therapy, Rituximab and DHAP (Cytarabine, Cisplatine, Dexamethasone)</measure>
    <time_frame>09-2012 to 06-2018 (up to six years)</time_frame>
    <description>In the part I (dose escalation of Temsirolimus) the primary objective is to establish a maximum tolerated dose of Temsirolimus in combination with Rituximab and DHAP.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety, Tolerability and Efficacy of a combination therapy of Temsirolimus added to the standard therapy, Rituximab and DHAP (Cytarabine, Cisplatine, Dexamethasone)</measure>
    <time_frame>09-2012 to 06-2018 (up to six years)</time_frame>
    <description>In the part I (dose escalation of Temsirolimus) secondary objective is to prove ability to mobilize stem cells in patients scheduled to high dose therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety, Tolerability and Efficacy of a combination therapy of Temsirolimus added to the standard therapy, Rituximab and DHAP (Cytarabine, Cisplatine, Dexamethasone)</measure>
    <time_frame>09-2012 to 06-2018 (up to six years)</time_frame>
    <description>In the part II (full target dose) the secondary objective is to evaluate Progression Free Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety, Tolerability and Efficacy of a combination therapy of Temsirolimus added to the standard therapy, Rituximab and DHAP (Cytarabine, Cisplatine, Dexamethasone)</measure>
    <time_frame>09-2012 to 06-2018 (up to six years)</time_frame>
    <description>In the part II (full target dose) the secondary objective is to evaluate Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety, Tolerability and Efficacy of a combination therapy of Temsirolimus added to the standard therapy, Rituximab and DHAP (Cytarabine, Cisplatine, Dexamethasone)</measure>
    <time_frame>09-2012 to 06-2018 (up to six years)</time_frame>
    <description>In the part II (full target dose) the secondary objective is to evaluate Toxicity</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Diffuse Large B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Rituximab, Temsirolimus, DHAP, intravenous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a multicenter, open label, single arm, phase II study. There will be no placebo usage within this trial. In the part I, dose escalation part, of this trial 6 patients will be included in each dose level. There will be 4 cohorts, administering up to a maximum of 4 cycles 25 mg, 50 mg, 75mg or 100mg Temsirolimus in combination with Rituximab and DHAP.
Treatment regimen part I:
Part I - Cohort A, B, C, D, X Temsirolimus 25 (A), 50 (B), 75 (C),100 (D) or 15 (X) mg, Day 1, 8, Rituximab (375 mg/m² day 2) Dexamethasone 40mg day 3-6 Cisplatine 100 mg/m² day 3 Cytarabine 2x2 g/m² day 4
...repeat day 22, up to a maximum of 4 cycles
In the part II of the trial 40 patients will be included to receive the full target dose, established within the part I of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab, Temsirolimus, DHAP, intravenous</intervention_name>
    <description>Maximum tolerated dose of Temsirolimus Rituximab (375 mg/m²) Dexamethasone (120 mg) Cisplatin (100mg/m²) Cytarabine (2x2g/m²))</description>
    <arm_group_label>Rituximab, Temsirolimus, DHAP, intravenous</arm_group_label>
    <other_name>Temsirolimus-R-DHAP</other_name>
    <other_name>Torisel</other_name>
    <other_name>MabThera</other_name>
    <other_name>Fortecortin</other_name>
    <other_name>ARA-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Depocyte</other_name>
    <other_name>R-DHAP</other_name>
    <other_name>Rituximab-DHAP</other_name>
    <other_name>Temsirolimus,Rituximab,Dexamethasone,Cisplatine,Cytarabine</other_name>
    <other_name>Temsirolimus-Rituximab-DHAP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically proven diagnosis of diffuse large cell B-cell lymphoma
             (DLBCL) according to the World Health Organization classification.

          -  Documented relapse or progression following at least one treatment but a maximum of 2
             prior treatments. Prior treatment must have included at least 3 cycles of
             anthracycline containing chemotherapy (e.g. CHOP-like)

          -  Any of the following: at least 1 measurable tumor mass (&gt;1.5 cm x &gt;1.0 cm),
             involvement of any organ or bone marrow infiltration

          -  Subjects 18 years or older

          -  Subjects (or their legally acceptable representatives) must have signed an informed
             consent document indicating that they understand the purpose of and procedures
             required for the study and are willing to participate in the study.

          -  Adequate bone marrow reserve: Platelets of at least 75000/µl, absolute neutrophil
             count at least 1500/µl

          -  Alanine aminotransferase (ALT) &lt; 2.5 x upper limit of normal (ULN); Aspartate
             aminotransferase (AST) &lt; 2.5 x ULN, Total bilirubin &lt; 1.5 x ULN

          -  Calculated creatinine clearance (MDRD) &gt; 70 mL/min

          -  Eastern Cooperative Oncology Group [ECOG] performance Status &lt; 3

          -  Female subject must be postmenopausal (for at least 6 months), surgically sterile,
             abstinent, or, if sexually active, be practicing an effective method of birth control
             (e.g., prescription oral contraceptives, contraceptive injections, intrauterine
             device, double-barrier method, contraceptive patch, male partner sterilization) before
             entry and throughout the study; and have a negative serum ß-hCG pregnancy test at
             screening

        Exclusion Criteria:

          -  Active central nervous System lymphoma. Brain MRI is required only if clinically
             indicated

          -  Pregnancy or breast feeding women

          -  Lymphoma other than DLBCL

          -  Severe concomitant disease (e.g. uncontrolled arterial hypertension, heart failure
             (NYHA III-IV), uncontrolled diabetes mellitus, pulmonary fibrosis, uncontrolled
             hyperlipoproteinemia)

          -  Active uncontrolled infections including HIV-positivity, active Hep B or C

          -  Mental status precluding patient's compliance

          -  Prior treatment with Temsirolimus

          -  Known CD20 negativity

          -  Patients refractory to DHAP in a prior treatment line

          -  Prior autologous or allogeneic stem cell or bone marrow transplantation

          -  Peripheral neuropathy or neuropathic pain of Grade 2 or worse

          -  Diagnosed or treated for a malignancy other than NHL except: adequately treated
             non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, DCIS of the
             breast, or other solid tumors curatively treated with no evidence of disease for &gt;5
             years

          -  Concurrent treatment with another investigational agent during the conduct of the
             trial.

          -  Concurrent participation in non-treatment studies is not excluded

          -  Known intolerance to Sirolimus or derivates, Cytarabine, Cisplatine or Rituximab.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathias Witzens-Harig, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Heidelberg, Department 5 Hematology, Oncology, Rheumatology, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Freiburg</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Heidelberg Hospital</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Erlangen</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ludwig-Maximilians-University of Munich</name>
      <address>
        <city>Munich</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Technische Universität München</name>
      <address>
        <city>Munich</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johann Wolfgang Goethe University Hospitals, Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Guttenberg University Mainz</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité University Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2012</study_first_submitted>
  <study_first_submitted_qc>July 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2012</study_first_posted>
  <last_update_submitted>October 26, 2016</last_update_submitted>
  <last_update_submitted_qc>October 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Mathias Witzens-Harig</investigator_full_name>
    <investigator_title>PD Dr. med. Mathias Witzens-Harig</investigator_title>
  </responsible_party>
  <keyword>Non Hodgkin´s Lymphoma</keyword>
  <keyword>Diffuse Large B-Cell Lymphoma</keyword>
  <keyword>Aggressive Lymphoma</keyword>
  <keyword>Aggressive Non Hodgkin´s Lymphoma</keyword>
  <keyword>NHL</keyword>
  <keyword>aNHL</keyword>
  <keyword>Temsirolimus</keyword>
  <keyword>Torisel</keyword>
  <keyword>Relapsed Non Hodgkin´s Lymphoma</keyword>
  <keyword>Relapsed Diffuse Large B-Cell Lymphoma</keyword>
  <keyword>aggressive NHL</keyword>
  <keyword>B-NHL</keyword>
  <keyword>aggressive B-NHL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

